High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)

被引：5

作者：

Goncalves, A.

Bachelot, T.

Lusque, A.

Arnedos, M.

Campone, M.

Bieche, I.

Lacroix, L.

Pierron, G.

Dalenc, F.

Filleron, T.

Sablin, M-P

Jimenez, M.

Ferrero, J-M

Lefeuvre-Plesse, C.

Bonnefoi, H.

Attignon, V.

Soubeyran, I.

Jezequel, P.

Commo, F.

Andre, F.

机构：

[1] Inst Paoli Calmettes, Marseille, France

[2] Ctr Leon Berard, Lyon, France

[3] Inst Claudius Regaud IUCT O, Toulouse, France

[4] Gustave Roussy Canc Campus, Villejuif, France

[5] Inst Cancerol Ouest, Nantes, France

[6] Inst Curie, Paris, France

[7] Unicancer, Paris, France

[8] Ctr Antoine Lacassagne, Nice, France

[9] Ctr Eugene Marquis, Rennes, France

[10] Inst Bergonie, Bordeaux, France

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS16-PD1-08

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD1-08

引用

页数：2